Saleem, Mohd Shahid Khan European Journal of Medical Research.2025;[Epub] CrossRef Evaluation of Selected Serum Adipocytokines in Patients with RelapsingRemitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs Boena Adamczyk, Natalia Morawiec, Robert Kwinta, Micha Rakoca, Sawomir Wawrzyniak, Jolanta Zalejska-Fiolka, Agata Sowa, Ksawier Sawa, Monika Adamczyk-Sowa International Journal of Molecular Sciences.2025
It can be helpful when navigating the complexity of insurance coverage for drugs like GLP-1s
"Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults"
This article has been viewed 430,075 times
The subscription blind spot: your genetics aren't in the plan A subscription can automate billing and refills, but it cannot describe the metabolic terrain a GLP-1 compound is prescribed into, and that terrain is partly genetic